HC Wainwright Reaffirms “Buy” Rating for Edesa Biotech (NASDAQ:EDSA)

Posted by Donna Armstrong on Mar 13th, 2025

Edesa Biotech (NASDAQ:EDSA – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $21.00 price objective on the stock.

Edesa Biotech Stock Performance

NASDAQ EDSA opened at $2.39 on Thursday. Edesa Biotech has a one year low of $1.55 and a one year high of $5.59. The company has a 50-day simple moving average of $2.07 and a 200-day simple moving average of $2.81. The firm has a market capitalization of $16.69 million, a PE ratio of -1.28 and a beta of 0.77.

Edesa Biotech (NASDAQ:EDSA – Get Free Report) last issued its earnings results on Friday, February 14th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.17). During the same quarter in the prior year, the business posted ($0.54) earnings per share. Equities analysts forecast that Edesa Biotech will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On Edesa Biotech

An institutional investor recently bought a new position in Edesa Biotech stock. Two Sigma Securities LLC acquired a new position in Edesa Biotech, Inc. (NASDAQ:EDSA – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 15,313 shares of the company’s stock, valued at approximately $26,000. Two Sigma Securities LLC owned 0.44% of Edesa Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 5.50% of the company’s stock.

About Edesa Biotech

(Get Free Report)

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.